Pacira Pharmaceuticals Reaches New 52-Week High at $102.29 (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) reached a new 52-week high on Monday , StockRatingsNetwork.com reports. The company traded as high as $102.29 and last traded at $101.09, with a volume of 226,332 shares changing hands. The stock had previously closed at $101.13.
PCRX has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of Pacira Pharmaceuticals from $98.00 to $110.00 in a research note on Friday, August 1st. Separately, analysts at Canaccord Genuity raised their price target on shares of Pacira Pharmaceuticals to $114.00 in a research note on Friday, August 1st. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Friday, August 1st. They now have a $109.00 price target on the stock, up previously from $86.00. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $104.68.
The stock’s 50-day moving average is $89. and its 200-day moving average is $76.52. The company’s market cap is $3.622 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, July 31st. The company reported $0.04 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.25. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $42.20 million. Pacira Pharmaceuticals’s revenue was up 175.2% compared to the same quarter last year. Analysts expect that Pacira Pharmaceuticals will post $-0.25 EPS for the current fiscal year.
In other Pacira Pharmaceuticals news, Insider Gary Patou unloaded 20,000 shares of the stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $100.26, for a total transaction of $2,005,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.